Rosen Law Firm Announces Investigation of Shengtai Pharmaceutical In Connection With Going Private P
Rosen Law Firm Announces Investigation of Shengtai Pharmaceutical In Connection With Going Private Proposal from its Chairman and CEO - SGTI
NEW YORK--(BUSINESS WIRE)-- The Rosen Law Firm is investigating the Board of Directors of Shengtai Pharmaceutical Inc. (OTC: SGTI) for possible breaches of fiduciary duty and other violations of state law in connection with a going private proposal from its Chairman and Chief Executive Officer.
If you would like to join the action please email or call Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at firstname.lastname@example.org or email@example.com. There is no cost or obligation to you.
Under the terms of the proposal, offered by SGTI's Chairman and CEO, Mr. Qingtai Liu, shareholders will receive $1.65 for each share of Shengtai Pharmaceutical stock they own. The investigation relates to whether the proposal for $1.65/share is fair to public shareholders and whether Shengtai Pharmaceutical's Board breached its fiduciary duties in connection with the offer.
If you own Shengtai Pharmaceutical common stock and wish to obtain additional information, you may contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
The Rosen Law Firm P.A.
Phillip Kim, Esq.
Laurence Rosen, Esq.
275 Madison Avenue 34th Floor
New York, New York 10016
Weekends Tel: 917-562-8616
Toll Free: 866-767-3653
KEYWORDS: United States North America New York
The article Rosen Law Firm Announces Investigation of Shengtai Pharmaceutical In Connection With Going Private Proposal from its Chairman and CEO - SGTI originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.